Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Maliheh Safavi, Reyhaneh Sabourian & Mohammad Abdollahi. (2016) The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opinion on Drug Discovery 11:10, pages 939-956.
Read now
Read now
Silvia Pandolfi & Barbara Stecca. (2015) Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy. Research and Reports in Biology 6, pages 55-71.
Read now
Read now
Articles from other publishers (45)
Kris Cooreman, Bart De Spiegeleer, Christof Van Poucke, David Vanavermaete, Daan Delbare, Evelien Wynendaele & Bavo De Witte. (2023) Emerging pharmaceutical therapies of Ascidian-derived natural products and derivatives. Environmental Toxicology and Pharmacology 102, pages 104254.
Crossref
Crossref
Md. Abu Sufian & Marc A. Ilies. (2022) Lipid‐based nucleic acid therapeutics with in vivo efficacy. WIREs Nanomedicine and Nanobiotechnology 15:2.
Crossref
Crossref
Kazuko Inoue, Toshiki Mochizuki, Nana Kasamori & Takafumi Komori. (2022) Determination of drug-to-antibody ratio of antibody–drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry. Bioanalysis 14:24, pages 1533-1545.
Crossref
Crossref
Ha Young Jang, In-Wha Kim & Jung Mi Oh. (2022) Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study. Frontiers in Oncology 12.
Crossref
Crossref
Ngoc Minh Nguyen & Jungsook Cho. (2022) Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance. International Journal of Molecular Sciences 23:3, pages 1733.
Crossref
Crossref
Jiachen Wen & M. Kyle Hadden. (2021) Medulloblastoma drugs in development: Current leads, trials and drawbacks. European Journal of Medicinal Chemistry 215, pages 113268.
Crossref
Crossref
Freideriki Michailidou, Tomas Lebl, Alexandra M. Z. Slawin, Sunil Vishnuprasadji Sharma, Murray J. B. Brown & Rebecca Jane Miriam Goss. (2020) Synthesis and Conformational Analysis of Fluorinated Uridine Analogues Provide Insight into a Neighbouring-Group Participation Mechanism. Molecules 25:23, pages 5513.
Crossref
Crossref
Marilia Barreca, Anastasios Stathis, Paola Barraja & Francesco Bertoni. (2020) An overview on anti-tubulin agents for the treatment of lymphoma patients. Pharmacology & Therapeutics 211, pages 107552.
Crossref
Crossref
Hang-Ping Yao, Sreedhar Reddy Suthe, Rachel Hudson & Ming-Hai Wang. (2020) Antibody–drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer. Drug Discovery Today 25:7, pages 1160-1173.
Crossref
Crossref
Philipp Berning, Carolin Hennemann, Claudia Tulotta, Christiane Schaefer, Birgit Lechtape, Marc Hotfilder, Yassmine El Gourari, Heribert Jürgens, Ewa Snaar-Jagalska, Georg Hempel, Uta Dirksen & Jenny Potratz. (2020) The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma. Cancers 12:4, pages 904.
Crossref
Crossref
Volker Schirrmacher. (2020) Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines 8:3, pages 61.
Crossref
Crossref
Hang-Ping Yao, Sreedhar Reddy Suthe, Xiang-Min Tong & Ming-Hai Wang. (2020) Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials. Therapeutic Advances in Medical Oncology 12, pages 175883592092006.
Crossref
Crossref
Saw Simeon & Nathjanan Jongkon. (2019) Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors. Molecules 24:23, pages 4393.
Crossref
Crossref
H. Christian Eberl, Thilo Werner, Friedrich B. Reinhard, Stephanie Lehmann, Douglas Thomson, Peiling Chen, Cunyu Zhang, Christina Rau, Marcel Muelbaier, Gerard Drewes, David Drewry & Marcus Bantscheff. (2019) Chemical proteomics reveals target selectivity of clinical Jak inhibitors in human primary cells. Scientific Reports 9:1.
Crossref
Crossref
Andrea Tumminia, Federica Vinciguerra, Miriam Parisi, Marco Graziano, Laura Sciacca, Roberto Baratta & Lucia Frittitta. (2019) Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk. International Journal of Molecular Sciences 20:12, pages 2863.
Crossref
Crossref
Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils, Emanuele Zucca, Anastasios Stathis, Matthias P. Wymann, Vladimir Cmiljanovic, Doriano Fabbro & Francesco Bertoni. (2019) The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers 11:6, pages 775.
Crossref
Crossref
Jonas Buck, Philip Grossen, Pieter R. Cullis, Jörg Huwyler & Dominik Witzigmann. (2019) Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery. ACS Nano 13:4, pages 3754-3782.
Crossref
Crossref
Anne-Marie Baird, David Easty, Monika Jarzabek, Liam Shiels, Alex Soltermann, Sonja Klebe, Stéphane Raeppel, Lauren MacDonagh, Chengguang Wu, Kim Griggs, Michaela B. Kirschner, Bryan Stanfill, Daisuke Nonaka, Chandra M. Goparaju, Bruno Murer, Dean A. Fennell, Dearbhaile M. O'Donnell, Martin P. Barr, Luciano Mutti, Glen Reid, Stephen Finn, Sinead Cuffe, Harvey I. Pass, Isabelle Opitz, Annette T. Byrne, Kenneth J. O'Byrne & Steven G. Gray. (2019) When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. Frontiers in Endocrinology 10.
Crossref
Crossref
Christopher A. Parks, Kalli R. HenningKevin D. PavelkoMichael J. HansenVirginia P. Van KeulenBrendan K. ReedJennifer D. StoneAdam G. SchrumDiana GilDavid M. KranzAndrew J. BordnerMichael A. Barry & Larry R. Pease. (2019) Breaking tolerance with engineered class I antigen-presenting molecules. Proceedings of the National Academy of Sciences 116:8, pages 3136-3145.
Crossref
Crossref
Behrouz Salehian, Simon Y Liem, Hoda Mojazi Amiri & Ellie Maghami. (2019) Clinical Trials in Management of Anaplastic Thyroid Carcinoma; Progressions and Set Backs: A Systematic Review. International Journal of Endocrinology and Metabolism In Press:In Press.
Crossref
Crossref
Silvia Pietrobono & Barbara Stecca. (2018) Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors. Cells 7:12, pages 272.
Crossref
Crossref
Sandeep K. Talapatra, Chuin Lean Tham, Paolo Guglielmi, Roberto Cirilli, Balakumar Chandrasekaran, Rajshekhar Karpoormath, Simone Carradori & Frank Kozielski. (2018) Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors. European Journal of Medicinal Chemistry 156, pages 641-651.
Crossref
Crossref
Lotte van Andel, Hilde Rosing, Jan Schellens & Jos Beijnen. (2018) Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment. Marine Drugs 16:7, pages 246.
Crossref
Crossref
Mark Wortinger, Jonathan Tetreault, Nick Loizos & Ling Liu. 2018. Extracellular Targeting of Cell Signaling in Cancer. Extracellular Targeting of Cell Signaling in Cancer
199
227
.
Silvia Benvenuti, Melissa Milan & Paolo M. Comoglio. 2018. Extracellular Targeting of Cell Signaling in Cancer. Extracellular Targeting of Cell Signaling in Cancer
1
43
.
Minhang Xin, Xinyue Ji, Ladie Kimberly De La Cruz, Suresh Thareja & Binghe Wang. (2018) Strategies to target the Hedgehog signaling pathway for cancer therapy. Medicinal Research Reviews 38:3, pages 870-913.
Crossref
Crossref
Jonas Schnittert, Ruchi Bansal, Gert Storm & Jai Prakash. (2018) Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Advanced Drug Delivery Reviews 129, pages 37-53.
Crossref
Crossref
Oleksandr O. Grygorenko, Angelina V. Biitseva & Serhii Zhersh. (2018) Amino sulfonic acids, peptidosulfonamides and other related compounds. Tetrahedron 74:13, pages 1355-1421.
Crossref
Crossref
Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, Sara De Dosso, Jens Weidmann, Anna Tessari, Hans Baumeister, Antje Danielczyk, Bruno Dietrich, Steffen Goletz, Alfredo Zurlo, Marc Salzberg, Cristiana Sessa & Luca Gianni. (2018) Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open 3:2, pages e000303.
Crossref
Crossref
Natalia V. Segatto, Mariana H. Remião, Kyle M. Schachtschneider, Fabiana K. Seixas, Lawrence B. Schook & Tiago Collares. (2017) The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery. Frontiers in Pharmacology 8.
Crossref
Crossref
Michele Graciotti, Cristiana Berti, Harm-Anton Klok & Lana Kandalaft. (2017) The era of bioengineering: how will this affect the next generation of cancer immunotherapy?. Journal of Translational Medicine 15:1.
Crossref
Crossref
Nancy A. Nixon, Omar F. Khan, Hasiba Imam, Patricia A. Tang, Jose Monzon, Haocheng Li, Gavin Sun, Doreen Ezeife, Sunil Parimi, Scot Dowden & Vincent C. Tam. (2017) Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014. Cancer 123:23, pages 4672-4679.
Crossref
Crossref
Paul A. Moore, Ross La Motte‐Mohs, Jonathan C. Li & Gurunadh R. Chichili. 2017. Protein Therapeutics. Protein Therapeutics
521
585
.
Yufeng Xiong, Yingsong Wu, Shuhong Luo, Yang Gao, Yujing Xiong, Daxiang Chen, Hao Deng, Wenbo Hao, Tiancai Liu & Ming Li. (2017) Development of a novel immunoassay to detect interactions with the transactivation domain of p53: application to screening of new drugs. Scientific Reports 7:1.
Crossref
Crossref
Everardo D. Saad, Xavier Paoletti, Tomasz Burzykowski & Marc Buyse. (2017) Precision medicine needs randomized clinical trials. Nature Reviews Clinical Oncology 14:5, pages 317-323.
Crossref
Crossref
Benoit Louage, Olivier De Wever, Wim E. Hennink & Bruno G De Geest. (2017) Developments and future clinical outlook of taxane nanomedicines. Journal of Controlled Release 253, pages 137-152.
Crossref
Crossref
Roderick L. BeijersbergenLodewyk F.A. WesselsRené Bernards. (2017) Synthetic Lethality in Cancer Therapeutics. Annual Review of Cancer Biology 1:1, pages 141-161.
Crossref
Crossref
Bert Müller & Marcel Van de VoordeJean‐Luc Coll & Jungyoon Choi. 2017. Nanoscience and Nanotechnology for Human Health. Nanoscience and Nanotechnology for Human Health
125
156
.
Denis L. Jardim, Eric S. Groves, Philip P. Breitfeld & Razelle Kurzrock. (2017) Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treatment Reviews 52, pages 12-21.
Crossref
Crossref
Jadd Shelton, Xiao Lu, Joseph A. Hollenbaugh, Jong Hyun Cho, Franck Amblard & Raymond F. Schinazi. (2016) Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. Chemical Reviews 116:23, pages 14379-14455.
Crossref
Crossref
Omid Zarei, Silvia Benvenuti, Fulya Ustun-Alkan, Maryam Hamzeh-Mivehroud & Siavoush Dastmalchi. (2016) Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. Journal of Cancer Research and Clinical Oncology 142:12, pages 2429-2446.
Crossref
Crossref
Alison M. Betts, Nahor Haddish-Berhane, John Tolsma, Paul Jasper, Lindsay E. King, Yongliang Sun, Subramanyam Chakrapani, Boris Shor, Joseph Boni & Theodore R. Johnson. (2016) Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. The AAPS Journal 18:5, pages 1101-1116.
Crossref
Crossref
Cian O. Malley & Graham P. Pidgeon. (2016) The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clinical 5, pages 29-40.
Crossref
Crossref
Corey Saba, Melissa Paoloni, Christina Mazcko, William Kisseberth, Jenna H. Burton, Annette Smith, Heather Wilson-Robles, Sara Allstadt, David Vail, Carolyn Henry, Susan Lana, E. J. Ehrhart, Brad Charles, Michael Kent, Jessica Lawrence, Kristine Burgess, Antonella Borgatti, Steve Suter, Paul Woods, Ira Gordon, Patricia Vrignaud, Chand Khanna & Amy K. LeBlanc. (2016) A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model. PLOS ONE 11:2, pages e0149194.
Crossref
Crossref
Silvia Pandolfi & Barbara Stecca. (2015) Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: implications for cancer therapy. Expert Reviews in Molecular Medicine 17.
Crossref
Crossref